Acumetis Launches as a Single Integrated Brand to Transform Life Sciences Commercialization
14.4.2026 14:06:00 CEST | Business Wire | Press release
Leading Pharmaceutical and Biotech Consultancies Combine to Create a Full-Service Commercialization Powerhouse Five leading life sciences organizations - Herspiegel, Adivo Associates, Decisive Consulting, Fiecon, and Sixsense Strategy Group - have come together as a single integrated brand to support better decision-making across the entire biopharma product lifecycle. The landmark move is inspired by the need to provide a new level of counsel and enhanced strategic clarity to clients operating in an age of complexity and rapid evolution. The combined businesses bring together more than 350 experts across the United States, Canada, UK, Europe, South America and Asia and covers Commercial Strategy, Launch Excellence, Patient Access and Support, Value and Access, Insights and Analytics, and Medical Affairs. This new brand and integrated commercial model mark a strategic milestone for Acumetis, launching 14 April 2026.
Acumetis - a new global commercialization company for the life sciences industry - launches today. The company, formed as a combination of five well-known specialist consultancies - Herspiegel, Adivo Associates, Decisive Consulting, Fiecon, and Sixsense Strategy Group - will provide enhanced strategic clarity and critical connection for life sciences businesses with products at all stages of development.
Acumetis is built around a single integrated commercial model and one leadership team, bringing together commercial, insights, medical, market access and patient strategy under one roof. The business offers capability and data to support clients across the product lifecycle, from evaluation and market access strategy through to launch execution and in-market performance.
Acumetis is purposefully built for the demands of modern life sciences commercialization. The name reflects the company's founding philosophy. ‘Acumen’ - the ability to make good judgments and discern what really matters - and ‘Metis’, the Greek concept of practical wisdom, together define an approach built on rigorous analysis, connected expertise, and measurable results for clients.
Brent Herspiegel, CEO of Acumetis, said: "Acumetis is designed to set a new standard in commercialization. Not just in capability, but in how that capability is delivered. For over two decades, the businesses that form Acumetis have supported more than 200 product launches for some of the most complex and high-stakes assets in life sciences. We’re now bringing our clients our full expertise as one integrated brand, helping them to make the right decision at the moments that matter most. For life sciences companies facing compressed timelines, increasing regulatory complexity and rising pressure to demonstrate value, this is a compelling value proposition.”
As a combined business, Acumetis will employ more than 350 specialists globally, with operational experience spanning more than 50 geographic markets. The company’s client base already includes more than 150 life sciences organizations, among them many of the world's top global pharmaceutical companies. The founding businesses have collectively supported more than 200 product launches and years of commercialization success.
The company is backed by DFW Capital, a leading middle-market private equity firm investing in companies that provide outsourced business, industrial, or healthcare services in regulated, compliance driven end-markets.
Acumetis is headquartered in Yardley, Pennsylvania, with additional offices across the United States, Canada, South America, United Kingdom, Europe and India. The company's website launches today at www.acumetisglobal.com.
Further information is available at www.acumetisglobal.com. Media enquiries should be directed to acumetis@woodrowcommunications.com.
About Acumetis
Acumetis is a global expert commercialization partner purposefully built to help life sciences win in the age of connectivity. With an integrated model spanning the entire asset lifecycle, deep functional and therapeutic-area expertise, and rigorous, outcome-driven thinking, Acumetis reframes complex problems and shapes solutions that are both imaginative and achievable. With more than 350 experts globally and experience across 50+ geographic markets, Acumetis helps clients unlock value, accelerate performance, and deliver better outcomes for patients.
Acumetis. Reframe what’s possible.
About DFW Capital
DFW Capital Partners is a middle-market private equity firm with over $2 billion in assets under management. The firm’s focus for the past 20 years has been investing in founder or management owned companies that provide outsourced business, industrial, or healthcare services in regulated, compliance driven end-markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260414569348/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Iconic Landmark Danjiang Bridge Opened to Redefine Taiwan18.5.2026 12:02:00 CEST | Press release
The Danjiang Bridge, one of Taiwan’s most significant recent public infrastructure projects, officially opened with a series of large-scale public events, transforming the bridge into a new cultural landmark and civic space. The program featured the “Danjiang Bridge Together Arts Festival,” immersive public activities, and a special performance of Light Chain by Cloud Gate Dance Theatre, symbolizing the integration of architecture, engineering, and the arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517667930/en/ The Danjiang Bridge is an iconic landmark in Taiwan with global recognition. (Photo via Highway Bureau , Motc) Spanning the mouth of the Tamsui River, the bridge serves as both a major transportation project and a recognizable architectural landmark, establishing a new urban symbol for Taiwan. Designed by Zaha Hadid Architects, the project gained international attention throughout its development and was sel
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 09:00:00 CEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 09:00:00 CEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 09:00:00 CEST | Press release
Expanded availability of LogicMonitor within Deutsche Telekom’s managed services portfolio follows successful operational use in the UKSelect outcomes include reduced reporting times and proactive incident preventionExpansion extends across DACH, Benelux, and the Nordics LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Throug
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 09:00:00 CEST | Press release
ZH9 is very well tolerated with a favourable safety profile, and no dose-limiting toxicities or Grade ≥3 drug-related adverse events reported.ZH9 demonstrates 91% freedom-from-relapse in NMIBC patients who have reached study end.Company plans to run a larger phase 2 study across a range of patient populations spanning intermediate risk and high risk including CIS. Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom